Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck

• Published in: ANZ journal of surgery 2009-01, Vol.79 (1-2), p.48-54
• Main Authors: Farhadieh, Ross D., Smee, Robert, Rees, Charles G. G., Salardini, Arash, Eggleton, Sarah, Yang, Jia-Lin, Russell, Pamela J.
• Format: Article
• Language: English
• Subjects: Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - metabolism; Carcinoma, Squamous Cell - pathology; Cell cycle; Cyclin A - metabolism; Cyclin A1; Disease-Free Survival; Female; Gene expression; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms - genetics; Head and Neck Neoplasms - metabolism; Head and Neck Neoplasms - pathology; head and neck squamous cell carcinoma; Humans; Immunohistochemistry; Laryngeal cancer; Laryngeal Neoplasms - genetics; Laryngeal Neoplasms - metabolism; Laryngeal Neoplasms - pathology; Male; Middle Aged; mut-p53; Mutation; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - metabolism; Neoplasms, Multiple Primary - genetics; Neoplasms, Multiple Primary - metabolism; Neoplasms, Multiple Primary - pathology; Pathology; Proteins; second primary tumour; survival; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism
• ISSN: 1445-1433; 1445-2197
• DOI: 10.1111/j.1445-2197.2008.04799.x

Background:  Field cancerization is a feature of head and neck squamous cell carcinoma. No biological marker in the index tumour has been correlated to the development of second primary tumours (SPT). Cyclin A1 is a cell cycle regulator and a downstream target of p53. This study assessed predictive correlation of cyclin A1 and mut‐p53 with clinicopathological parameters and occurrence of (SPT) 7in the head and neck. Methods:  Using immunohistochemistry 106 patients treated for primary laryngeal squamous cell carcinoma were investigated for expression of cyclin A1 and mut‐p53. Results:  Expression of cyclin A1 and mut‐p53 were noted in 83 of 106 (78.3%) and 25 of 106 (23.6%) patients. There was a weak but significant correlation between mut‐p53 and cyclin A1 (r = 0.301, P = 0.002) expression. During the follow‐up period (median 41.0 months (range 1–205 months)), 21 of 106 (19.8%) patients developed an SPT. There was no statistically significant correlation between the markers investigated and disease recurrence, SPT diagnosis or clinicopathological parameters. Conclusion:  Second primary tumours are an intriguing problem in treatment of HNSCC and a predictive marker identifying those greatest at risk would be a leap forward.